Castlight Health Announces First Quarter 2016 Results
Total Revenue of $22.7 Million, Up 42% Year Over Year
/EINPresswire.com/ -- SAN FRANCISCO, CA--(Marketwired - May 10, 2016) - Castlight Health, Inc. (NYSE: CSLT), a leading health benefits platform provider, today announced results for its first quarter ended March 31, 2016.
"During the first quarter, we continued to make progress on key initiatives such as developing channel and ecosystem relationships, as well as successfully deploying our solutions including our newest products. As such, we were able to exceed our first quarter revenue guidance and improve our gross margins. However, the closing of deals is taking longer than we expected and we are moderating our ARR growth expectations for the year," said Giovanni Colella, M.D., co-founder and chief executive officer of Castlight Health. "We are instituting a cost reduction program designed to reduce our operating expenses to further lower our operating losses and help enable us to achieve our goal of being cash flow break-even by mid-2017. At the same time, we plan to maintain investments in innovation and customer success that we believe will power our long-term growth on a sustained basis."
Financial Performance for the Three Months Ended March 31, 2016
- Total revenue for the first quarter of 2016 was $22.7 million, an increase of 42% from the first quarter of 2015. Subscription revenue was $21.0 million, an increase of 41% on a year-over-year basis.
- Gross margin for the first quarter of 2016 was 59.3%, compared to a gross margin of 55.0% in the first quarter of 2015. Non-GAAP gross margin for the first quarter of 2016 was 62.9% compared to a non-GAAP gross margin of 58.1% in the first quarter of 2015.
- Operating loss for the first quarter of 2016 was $21.4 million, compared to an operating loss of $19.7 million in the first quarter of 2015. Non-GAAP operating loss for the first quarter of 2016 was $13.0 million, compared to a non-GAAP operating loss of $16.1 million in the first quarter of 2015.
- Net loss per basic and diluted share was $0.22 in the first quarter of 2016, compared to a net loss per basic and diluted share of $0.21 in the first quarter of 2015. The non-GAAP net loss per basic and diluted share for the first quarter of 2016 was $0.13, compared to a net loss per basic and diluted share of $0.17 in the first quarter of 2015. For both GAAP and non-GAAP purposes, the weighted average basic and diluted share count for the first quarter of 2016 was 96.3 million compared to 91.8 million in the first quarter of 2015.
- Total cash, cash equivalents and marketable securities were $120.5 million at the end of the first quarter of 2016. Cash used in operations for the first quarter of 2016 was $14.0 million, compared to $13.2 million used in operations in the first quarter of 2015.
A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures".
Business Outlook
Q2 2016 Guidance: Revenue for the company's second quarter is expected to be $22.8 million to $23.1 million. We expect to generate a non-GAAP operating loss in the range of $12.5 million to $13.5 million and a non-GAAP net loss per share of $0.13 to $0.14 based on 97 million weighted average basic and diluted shares outstanding.
Full Year 2016 Guidance: Revenue for the company's full year 2016 is expected to be in the range of $99.0 million to $102.0 million, an increase of 31% - 35% year-over-year. Non-GAAP operating loss is expected to be in the range of $40.0 million to $42.0 million. Non-GAAP net loss per share is expected to be in the range of $0.41 to $0.43 based on 97 million to 98 million weighted average basic and diluted common shares outstanding.
The company's revised non-GAAP operating loss guidance reflects the expected financial impact of the reduction in force effective in the second quarter of 2016.
For both the second quarter and the full year 2016, non-GAAP guidance excludes the effects of stock-based compensation expense, capitalization and amortization of internal-use software, and the impact of the restructuring charge expected to be taken in the second quarter of 2016.
Quarterly Conference Call
Castlight Health will host a conference call to discuss its first quarter 2016 results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the company's Investor Relations website at http://ir.castlighthealth.com. In addition, an archive of the webcast can be accessed through the same link. Participants who choose to call in to the conference call can do so by dialing 1-877-201-0168. The conference ID number is 86434239. A replay will be available for one week at 1-855-859-2056, passcode 86434239.
About Castlight Health
Our mission is to empower people to make the best choices for their health and to help companies make the most of their health benefits. We offer a health benefits platform that engages employees to make better healthcare decisions and can guide them to the right program, care, and provider. The platform also enables benefit leaders to communicate and measure their programs while driving employee engagement with targeted, relevant communications. Castlight has partnered with enterprise customers, spanning millions of lives, to improve healthcare outcomes, lower costs, and increase benefits satisfaction.
For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook.
Non-GAAP Financial Measures
To supplement Castlight Health's financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross margin, non-GAAP operating expense, non-GAAP operating loss, non-GAAP net loss and non-GAAP net loss per share. These non-GAAP financial measures differ from GAAP financial measures in that they exclude stock-based compensation, warrant expense, litigation settlement, capitalization and amortization of internal-use software and the associated tax impact of these items, where applicable.
We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company's core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company's historical financial performance.
We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the second quarter of 2016 and full year 2016 to comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation expense and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP operating loss. The factors that may impact our future stock-based compensation expense and capitalization and amortization of internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort.
These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company's financial information in its entirety and not rely on a single financial measure.
Safe Harbor For Forward-Looking Statements
This press release contains forward-looking statements about Castlight Health's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health's second quarter and 2016 full year projections, our expectations for future performance of our business, market growth and business conditions, future innovation by the company and future developments with respect to the digital healthcare industry. Statements including words such as "anticipate," "believe," "estimate," "will," "continue," "expect," or "future," and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health's documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.
Copyright 2016 Castlight Health, Inc. Castlight Health
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
As of
---------------------------
March 31, December 31,
2016 2015
------------- -------------
(unaudited)
Assets
Current assets:
Cash and cash equivalents $ 35,111 $ 19,150
Marketable securities 85,385 101,274
Accounts receivable, net 14,033 12,751
Deferred commissions 4,627 5,438
Prepaid expenses and other current assets 4,314 3,772
------------- -------------
Total current assets 143,470 142,385
Property and equipment, net 6,612 6,896
Marketable securities, noncurrent - 13,335
Restricted cash, noncurrent 1,000 1,000
Deferred commissions, noncurrent 4,861 4,923
Other assets 4,669 4,735
------------- -------------
Total assets $ 160,612 $ 173,274
============= =============
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 4,105 $ 3,384
Accrued expenses and other current liabilities 7,111 4,550
Accrued compensation 5,249 11,477
Deferred revenue 31,622 26,590
------------- -------------
Total current liabilities 48,087 46,001
Deferred revenue, noncurrent 6,902 7,522
Other liabilities, noncurrent 1,761 1,397
------------- -------------
Total liabilities 56,750 54,920
Stockholders' equity 103,862 118,354
------------- -------------
Total liabilities and stockholders' equity $ 160,612 $ 173,274
============= =============
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
Three Months Ended March 31,
----------------------------
2016 2015
------------- -------------
Revenue:
Subscription $ 21,037 $ 14,906
Professional services 1,680 1,045
------------- -------------
Total revenue 22,717 15,951
------------- -------------
Cost of revenue:
Cost of subscription (1) 4,136 2,519
Cost of professional services (1) 5,113 4,653
------------- -------------
Total cost of revenue 9,249 7,172
------------- -------------
Gross profit 13,468 8,779
------------- -------------
Operating expenses:
Sales and marketing (1) 16,282 16,463
Research and development (1) 10,085 6,594
General and administrative (1) 8,545 5,463
------------- -------------
Total operating expenses 34,912 28,520
------------- -------------
Operating loss (21,444) (19,741)
Other income, net 89 98
------------- -------------
Net loss $ (21,355) $ (19,643)
============= =============
Net loss per share, basic and diluted $ (0.22) $ (0.21)
============= =============
Weighted-average shares used to compute basic
and diluted net loss per share 96,291 91,786
============= =============
_______________________
(1) Includes stock-based compensation expense as follows:
Three Months Ended March 31,
-----------------------------
2016 2015
-------------- --------------
Cost of revenue:
Cost of subscription $ 108 $ 33
Cost of professional services 477 425
Sales and marketing 2,235 1,751
Research and development 1,405 633
General and administrative 1,269 1,027
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
Three Months Ended March 31,
----------------------------
2016 2015
------------- -------------
Operating activities:
Net loss $ (21,355) $ (19,643)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation 783 454
Stock-based compensation 5,494 3,869
Amortization of deferred commissions 1,162 857
Accretion and amortization of marketable
securities 176 443
Changes in operating assets and liabilities:
Accounts receivable (1,282) 609
Deferred commissions (289) (638)
Prepaid expenses and other assets 36 30
Accounts payable 605 1,512
Accrued expenses and other liabilities (3,732) (4,403)
Deferred revenue 4,412 3,721
------------- -------------
Net cash used in operating activities (13,990) (13,189)
------------- -------------
Investing activities:
Purchase of property and equipment (466) (887)
Purchase of marketable securities (29,486) (13,034)
Sales of marketable securities - 5,000
Maturities of marketable securities 58,637 30,180
------------- -------------
Net cash provided by investing activities 28,685 21,259
------------- -------------
Financing activities:
Proceeds from the exercise of stock options 1,266 1,640
Payments of deferred financing costs - (94)
------------- -------------
Net cash provided by financing activities 1,266 1,546
------------- -------------
Net increase in cash and cash equivalents 15,961 9,616
Cash and cash equivalents at beginning of
period 19,150 17,425
------------- -------------
Cash and cash equivalents at end of period $ 35,111 $ 27,041
============= =============
CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)
Three Months Ended
-----------------------------------------
March 31, December 31, March 31,
2016 2015 2015
---------- ------------- ----------
Gross profit:
GAAP gross profit
subscription $ 16,901 $ 16,048 $ 12,387
GAAP gross margin
subscription 80.3 % 80.5 % 83.1 %
Stock-based compensation
expense 108 87 33
Amortization of internal-
use software 244 124 24
---------- ------------- ----------
Non-GAAP gross profit
subscription $ 17,253 $ 16,259 $ 12,444
========== ============= ==========
Non-GAAP gross margin
subscription 81.9 % 81.6 % 83.5 %
GAAP gross loss professional
services $ (3,433) $ (4,388) $ (3,608)
GAAP gross loss percentage
professional services (204 ) % (318 ) % (345 ) %
Stock-based compensation
expense 477 653 425
Capitalization of
internal-use software - (30) -
---------- ------------- ----------
Non-GAAP gross loss
professional services $ (2,956) $ (3,765) $ (3,183)
========== ============= ==========
Non-GAAP gross loss
percentage professional
services (176 ) % (272 ) % (305 ) %
GAAP gross profit $ 13,468 $ 11,660 $ 8,779
GAAP gross margin 59.3 % 54.7 % 55.0 %
Impact of non-GAAP
adjustments 829 834 482
---------- ------------- ----------
Non-GAAP gross profit $ 14,297 $ 12,494 $ 9,261
========== ============= ==========
Non-GAAP gross margin 62.9 % 58.6 % 58.1 %
Operating expense:
GAAP sales and marketing $ 16,282 $ 16,579 $ 16,463
Stock-based compensation
expense (2,235) (1,822) (1,751)
---------- ------------- ----------
Non-GAAP sales and marketing $ 14,047 $ 14,757 $ 14,712
========== ============= ==========
GAAP research and development $ 10,085 $ 8,224 $ 6,594
Stock-based compensation
expense (1,405) (1,154) (633)
Capitalization of
internal-use software - 620 282
---------- ------------- ----------
Non-GAAP research and
development $ 8,680 $ 7,690 $ 6,243
========== ============= ==========
GAAP general and
administrative $ 8,545 $ 5,983 $ 5,463
Stock-based compensation
expense (1,269) (1,069) (1,027)
Litigation Settlement (2,735) - -
---------- ------------- ----------
Non-GAAP general and
administrative $ 4,541 $ 4,914 $ 4,436
========== ============= ==========
GAAP operating expense $ 34,912 $ 30,786 $ 28,520
Impact of non-GAAP
adjustments (7,644) (3,425) (3,129)
---------- ------------- ----------
Non-GAAP operating expense $ 27,268 $ 27,361 $ 25,391
Operating loss:
GAAP operating loss $ (21,444) $ (19,126) $ (19,741)
Impact of non-GAAP
adjustments 8,473 4,259 3,611
---------- ------------- ----------
Non-GAAP operating loss $ (12,971) $ (14,867) $ (16,130)
========== ============= ==========
Net loss and net loss per
share:
GAAP net loss $ (21,355) $ (19,058) $ (19,643)
Total pre-tax impact of
non-GAAP adjustments 8,473 4,259 3,611
Income tax impact of non-
GAAP adjustments - - -
---------- ------------- ----------
Non-GAAP net loss $ (12,882) $ (14,799) $ (16,032)
========== ============= ==========
Basic and Diluted net loss
per share
GAAP $ (0.22) $ (0.20) $ (0.21)
========== ============= ==========
Non-GAAP $ (0.13) $ (0.16) $ (0.17)
========== ============= ==========
Shares used in basic and
diluted net loss per share
computation 96,291 94,969 91,786
========== ============= ==========
Investor Contact:
Ann Hickey
ir@castlighthealth.com
415-829-1400
Media Contact:
Jim Rivas
press@castlighthealth.com
415-829-1568
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
